TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the retirement of Chief Financial Officer Tom Fitzgerald, who has served in the role since July 2018. Fitzgerald will resign as CFO and a director effective immediately but will continue to provide transition services. The company named John Tattory interim CFO, effective immediately.
Tattory brings more than 25 years of financial and operational management and leadership experience across pharmaceutical, medical device and biotechnology companies. His background includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics and Windtree Therapeutics. He currently serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies. This depth of experience is expected to be invaluable as TransCode continues to advance its pipeline.
The leadership change comes at a critical time for TransCode. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. Tattory’s financial stewardship will be crucial in guiding the company through clinical development and potential commercialization.
Investors and stakeholders can view the full press release at https://nnw.fm/8G3ik. For ongoing news and updates relating to RNAZ, the company’s newsroom is available at https://nnw.fm/RNAZ.
The appointment of an interim CFO with Tattory’s extensive life science financial experience ensures continuity in TransCode’s financial operations as it pursues its mission to develop innovative cancer therapies. The company remains focused on advancing its immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers.
